MedTrace Logo

Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients

NCT03982238 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-04-03

No results posted yet for this study

Summary

The study will assess the total testosterone and sex hormone-binding globulin levels in men with type 2 diabetes before and after continuous subcutaneous insulin infusion and hypoglycemic drugs treatment.

Conditions

Interventions

DRUG

Insulin

Continuous subcutaneous insulin infusion therapy for 1 month

DRUG

Metformin

Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month

DRUG

Dapagliflozin

Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month

Sponsors & Collaborators

  • Majianhua

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2019-11-15
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982238 on ClinicalTrials.gov